Panacea Biotec

Why is Panacea Biotec Ltd falling/rising?

As of 14-Jun, Panacea Biotec Ltd's stock price is rising to Rs 537.30, reflecting a 2.23% increase after two days of decline. However, concerns about the company's long-term fundamentals and declining investor interest may pose risks for future performance.

As of 14-Jun, Panacea Biotec Ltd's stock price is rising, currently at Rs 537.30, reflecting an increase of Rs 11.7 or 2.23%. This upward movement follows a trend reversal, as the stock has gained after two consecutive days of decline. Additionally, the stock has outperformed its sector by 1.88% today and reached an intraday high of Rs 546, marking a 3.88% increase.<BR><BR>In the longer term, Panacea Biotec has demonstrated strong performance, with a 47.27% increase over the past month and a remarkable 310.47% rise over the last three years, significantly outperforming the Sensex during these periods. Despite this positive performance, there are concerns regarding the company's long-term fundamentals, including a weak average Return on Equity (ROE) of 0% and a negative EBITDA of Rs -4.66 crore. <BR><BR>Moreover, the company's ability to service its debt is questionable, as indicated by a poor EBIT to Interest ratio of -13.79. The stock's liquidity remains adequate for trading, but a notable decline in delivery volume by 56.75% against the 5-day average suggests a decrease in investor participation. <BR><BR>Overall, while the stock is currently rising due to short-term performance and a trend reversal, underlying fundamental weaknesses and declining investor interest may pose risks for future performance.

Which are the latest news on Panacea Biotec?

How big is Panacea Biotec?

As of 10th June, Panacea Biotec Ltd has a market capitalization of 3,456.00 Cr and reported Net Sales of 639.77 Cr with a Net Profit loss of 5.37 Cr over the latest 4 quarters. Shareholder's Funds are valued at 834.79 Cr, and Total Assets amount to 1,289.75 Cr.

As of 10th June, Panacea Biotec Ltd has a market capitalization of 3,456.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest 4 quarters, the company reported Net Sales of 639.77 Cr. However, it experienced a loss of 5.37 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2025. Shareholder's Funds are valued at 834.79 Cr, while Total Assets amount to 1,289.75 Cr.

Who are in the management team of Panacea Biotec?

The management team of Panacea Biotec includes Soshil Kumar Jain (Chairman & Executive Director), Rajesh Jain (Chairman & Managing Director), Sandeep Jain (Joint Managing Director), Vinod Goel (Group CFO & Company Secretary), and Ankesh Jain (Whole-time Director), along with several non-executive and independent directors. This team is responsible for guiding the company's strategic direction and operations.

The management team of Panacea Biotec includes the following key individuals:<BR><BR>1. **Soshil Kumar Jain** - Chairman & Executive Director<BR>2. **Rajesh Jain** - Chairman & Managing Director<BR>3. **Sandeep Jain** - Joint Managing Director<BR>4. **Vinod Goel** - Group CFO & Company Secretary<BR>5. **Ankesh Jain** - Whole-time Director<BR><BR>Additionally, the board includes several non-executive and independent directors:<BR><BR>- **R L Narasimhan**<BR>- **N N Khamitkar**<BR>- **K M Lal**<BR>- **Manjula Upadhyay**<BR>- **Mukul Gupta**<BR>- **Bhupinder Singh**<BR><BR>Lastly, **Narotam Kumar Juneja** serves as a director. This team plays a crucial role in steering the company's strategic direction and operations.

Who are the peers of the Panacea Biotec?

Panacea Biotec's peers include Orchid Pharma, Advanced Enzyme, IOL Chemicals, RPG LifeScience, Gufic BioScience, SMS Pharma, Aarti Drugs, Novartis India, Dishman Carbogen, and Zota Health Care. In terms of management risk, Panacea Biotec is rated Below Average, with a 1-year return of 17.08%, higher than Dishman Carbogen but lower than IOL Chemicals' 43.27%.

Peers: The peers of Panacea Biotec are Orchid Pharma, Advanced Enzyme, IOL Chemicals, RPG LifeScience, Gufic BioScience, SMS Pharma, Aarti Drugs, Novartis India, Dishman Carbogen, and Zota Health Care.<BR><BR>Quality Snapshot: Excellent management risk is observed at Advanced Enzyme, IOL Chemicals, and RPG LifeScience, while Average management risk is found at Gufic BioScience, SMS Pharma, Aarti Drugs, and Novartis India, and the rest. Below Average management risk is noted for Orchid Pharma, Panacea Biotec, and Dishman Carbogen. Growth ratings are Good for Novartis India, Below Average for Orchid Pharma, Advanced Enzyme, IOL Chemicals, RPG LifeScience, Gufic BioScience, SMS Pharma, Aarti Drugs, Panacea Biotec, and the rest. Capital Structure is Excellent for Advanced Enzyme, IOL Chemicals, and RPG LifeScience, Good for Aarti Drugs, Average for Gufic BioScience and SMS Pharma, and Below Average for Orchid Pharma, Panacea Biotec, and Dishman Carbogen.<BR><BR>Return Snapshot: IOL Chemicals has the highest 1-year return at 43.27%, while Dishman Carbogen has the lowest at -38.27%. Panacea Biotec's 1-year return of 17.08% is higher than Dishman Carbogen's but lower than IOL Chemicals'. Additionally, Dishman Carbogen and Aarti Drugs have negative six-month returns.

What does Panacea Biotec do?

Panacea Biotec Ltd is a leading Indian health management company in the Pharmaceuticals & Biotechnology sector, with a market cap of INR 3,456 Cr and reported net sales of 167 Cr and a net profit of 1 Cr for March 2026. Founded in 1984, it focuses on research-based products and has a negative return on equity of -2.31%.

Overview: <BR>Panacea Biotec Ltd is India's leading research-based health management company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Small Cap.<BR><BR>History: <BR>Panacea Biotec was incorporated on February 2, 1984, originally under the name Panacea Drug (P) Ltd. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 167 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 3,456 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.06 <BR>Return on Equity: -2.31% <BR>Price to Book: 4.46<BR><BR>Contact Details: <BR>Address: Ambala-Chandigarh Highway, Lalru Punjab: 140501 <BR>Tel: 91-1762-505900 <BR>Email: companysec@panaceabiotec.com <BR>Website: http://www.panaceabiotec.com

Should I buy, sell or hold Panacea Biotec Ltd?

Are Panacea Biotec Ltd latest results good or bad?

Panacea Biotec Ltd's latest Q4 FY26 results show a 25.82% increase in net sales to ₹166.75 crores, but the company reported a net loss of ₹1.00 crore, reflecting significant profitability challenges and a sharp decline in operating margins. Overall, while revenue growth is positive, the inability to achieve profitability raises concerns about the company's structural weaknesses.

Panacea Biotec Ltd's latest results for Q4 FY26 indicate a challenging situation for the company. While net sales reached ₹166.75 crores, marking a 25.82% increase year-on-year and an all-time quarterly high, the company reported a net loss of ₹1.00 crore. This represents a significant decline of 86.93% quarter-on-quarter and a staggering 127.51% year-on-year deterioration in profitability.<BR><BR>The operating margin saw a dramatic collapse, falling to just 1.54% from 7.11% in the previous quarter, highlighting severe cost pressures that overshadowed the revenue growth. This marks the third quarterly loss in the past eight quarters, underscoring persistent operational challenges.<BR><BR>Overall, while the revenue growth is a positive sign, the inability to translate that into profitability, combined with the sharp decline in margins, paints a concerning picture for Panacea Biotec. The results suggest that the company is facing significant structural weaknesses that need to be addressed for a turnaround.

When is the next results date for Panacea Biotec Ltd?

The next results date for Panacea Biotec Ltd is 30 May 2026.

The next results date for Panacea Biotec Ltd is scheduled for 30 May 2026.

Is Panacea Biotec technically bullish or bearish?

As of December 1, 2025, Panacea Biotec's technical trend is bearish, supported by bearish signals from the weekly MACD and KST, daily moving averages, and a lack of strong indicators from the RSI and Dow Theory, despite mildly bullish monthly Bollinger Bands.

As of 1 December 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Panacea Biotec is bearish, with a moderate strength indicated by the weekly MACD and KST both showing bearish signals. The daily moving averages also confirm a bearish outlook. Although the monthly Bollinger Bands are mildly bullish, they do not outweigh the bearish indicators present in the weekly timeframe. Overall, the lack of significant signals from the RSI and Dow Theory further supports a bearish sentiment.

How has been the historical performance of Panacea Biotec?

Panacea Biotec's historical performance shows fluctuating financial metrics, with stable net sales but increasing operating losses, resulting in a decline in profit before and after tax. Despite a slight increase in total assets and improved cash flow from investing activities, the company faces challenges in profitability.

Answer:<BR>The historical performance of Panacea Biotec shows a fluctuating trend in its financial metrics over the years.<BR><BR>Breakdown:<BR>Panacea Biotec's net sales have remained relatively stable, with a slight decrease from 559.17 crore in March 2024 to 559.09 crore in March 2025, following a notable drop from 661.23 crore in March 2022. The total operating income mirrored this trend, peaking at 661.23 crore in March 2022 before declining to 559.09 crore in March 2025. The company's total expenditure, excluding depreciation, increased from 579.23 crore in March 2024 to 585.00 crore in March 2025, contributing to an operating loss of 25.91 crore in March 2025, compared to a loss of 20.06 crore in March 2024. Profit before tax also saw a decline, moving from a profit of 1.48 crore in March 2024 to a loss of 7.95 crore in March 2025. Consequently, the profit after tax worsened from a loss of 1.50 crore in March 2024 to a loss of 8.72 crore in March 2025. The company's total assets increased slightly from 1,240.82 crore in March 2024 to 1,289.75 crore in March 2025, while total liabilities also rose from 1,240.82 crore to 1,289.75 crore during the same period. Cash flow from operating activities remained negative at -27.00 crore in March 2025, although cash flow from investing activities improved significantly to 64.00 crore. Overall, the financial performance of Panacea Biotec reflects challenges in profitability despite stable revenue figures.

Who are the top shareholders of the Panacea Biotec?

The top shareholder of Panacea Biotec is Dr. Rajesh Jain, who holds 49.33% of the shares. Individual investors own 18.45%, while 14 foreign institutional investors hold a combined 1.16%, with no mutual funds currently invested.

The top shareholders of Panacea Biotec include the promoters, with Dr. Rajesh Jain holding the highest stake at 49.33%. There are no pledged promoter holdings, and individual investors collectively hold 18.45% of the shares. Additionally, 14 foreign institutional investors (FIIs) hold a combined 1.16% of the company. There are no mutual funds currently holding shares in Panacea Biotec.

Is Panacea Biotec overvalued or undervalued?

As of November 13, 2020, Panacea Biotec is considered risky and overvalued with a negative PE ratio of -61.96 and an EV to EBITDA of -103.02, significantly worse than its peers, despite a 252.56% return over the past year.

As of 13 November 2020, the valuation grade for Panacea Biotec has moved from very expensive to risky, indicating a significant shift in its perceived value. The company is currently assessed as overvalued, given its negative PE ratio of -61.96 and EV to EBITDA ratio of -103.02, which are starkly contrasting with its peers. The Price to Book Value stands at 3.30, suggesting that the market is pricing the company at a premium despite its financial struggles.<BR><BR>In comparison to its peers, Panacea Biotec's ratios are considerably worse; for instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE of 22.99 and an EV to EBITDA of 15.93. These comparisons highlight the challenges Panacea Biotec faces in the market. Additionally, while the company has shown impressive returns over the past year at 252.56%, this performance is not enough to justify its current valuation in light of its financial metrics.

Has Panacea Biotec declared dividend?

Yes, Panacea Biotec Ltd has declared a 75% dividend, amounting to ₹0.75 per share, with an ex-date of September 19, 2011. However, the dividend yield is 0%, as it has not contributed to returns in recent periods, despite significant price returns.

Panacea Biotec Ltd has declared a 75% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 75%<BR>- Amount per share: 0.75<BR>- Ex-date: 19 Sep 11<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 2.49%, the dividend return was 0%, resulting in a total return of 2.49%.<BR><BR>For the 1-year period, the price return was 253.27%, the dividend return was 0%, leading to a total return of 253.27%.<BR><BR>Over the 2-year period, the price return was 272.84%, with a dividend return of 0%, culminating in a total return of 272.84%.<BR><BR>In the 3-year period, the price return was 203.06%, the dividend return was 0%, resulting in a total return of 203.06%.<BR><BR>For the 4-year period, the price return was 15.05%, with a dividend return of 0%, leading to a total return of 15.05%.<BR><BR>In the 5-year period, the price return was 177.17%, the dividend return was 0%, culminating in a total return of 177.17%.<BR><BR>Overall, while Panacea Biotec has declared a dividend, the dividend yield is 0%, indicating that the dividend has not contributed to returns in recent periods. The company has experienced significant price returns over various periods, suggesting strong performance in its stock value.